Dr. Vivek's AI Dr. Vivek's AI
Support us
🔗 You are viewing a shared knowledge page for: Fsgs
← New Search

Fsgs

Educational clinical summary of Fsgs for doctors and students: definition, workup, management, and key caveats. Not a substitute for guidelines.

Maintained by Dr. Vivek Karn Review process: editorial policy

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional based on the individual patient's condition, medical history, and current evidence. This content is not a substitute for professional medical judgment.

Overview

  • Definition: Focal Segmental Glomerulosclerosis (FSGS) is a clinicopathologic syndrome characterized by segmental sclerosis (scarring) and hyalinosis of some (focal) glomeruli, while others are spared, and only a portion of the affected glomerulus (segmental) is involved. It is a common cause of nephrotic syndrome and progressive kidney disease, often leading to end-stage renal disease (ESRD).
  • Epidemiology:
    • Incidence: Variable globally, but increasing. It is estimated to be 7-15 cases per million population per year.
    • Prevalence: Accounts for 20-30% of all adult cases of nephrotic syndrome and up to 50% in African Americans. It is the most common primary glomerular disease causing ESRD in the United States.
    • Demographics: Affects all ages, but peak incidence is in young adults and adolescents. Higher prevalence and worse prognosis observed in individuals of African descent. Gender distribution is roughly equal.
  • Classification: FSGS is primarily classified based on its presumed etiology and histological variants.
    • I. Primary (Idiopathic) FSGS: No identifiable underlying cause. Believed to be caused by a circulating permeability factor that damages podocytes.
    • II. Secondary FSGS: Identifiable underlying cause leading to podocyte injury or adaptive hyperfiltration.
      • Genetic/Familial: Caused by mutations in genes encoding podocyte proteins (e.g., NPHS1, NPHS2, TRPC6, ACTN4, WT1, INF2, COQ6, PAX2). Often presents in childhood or with steroid resistance.
      • Drug-induced: Lithium, interferon-alpha/beta, pamidronate, heroin, anabolic steroids, calcineurin inhibitors (CNIs, as a rare complication).
      • Viral-associated: HIV-associated nephropathy (HIVAN), parvovirus B19, CMV.
      • Maladaptive/Adaptive (Hyperfiltration-related): Occurs in response to sustained increased glomerular pressure or reduced nephron mass. Examples include severe obesity (obesity-related glomerulopathy), reflux nephropathy, unilateral nephrectomy, cyanotic congenital heart disease, sickle cell disease, chronic transplant glomerulopathy.
      • Other disease-associated: Chronic pyelonephritis, chronic transplant injury, focal proliferative glomerulonephritis resolving, IgA nephropathy resolving.
    • III. FSGS Variants (Columbia Classification): Based on histological patterns seen on biopsy, which can have prognostic implications.
      • Collapsing Variant: Rapidly progressive course, often associated with viral infections (e.g., HIV) or drug toxicity. Characterized by global collapse of the glomerular tuft and prominent podocyte hyperplasia.
      • Tip Variant: More favorable prognosis, often responsive to corticosteroids. Lesion involves the glomerular tuft adjacent to the tubular pole.
      • Cellular Variant: Characterized by endocapillary and/or extracapillary hypercellularity involving at least one segment of the glomerulus. Prognosis is intermediate.
      • Perihilar Variant: Sclerosis located at the vascular pole. Often associated with adaptive hyperfiltration.
      • Not Otherwise Specified (NOS): Most common type, all other forms of FSGS.

Pathophysiology

  • Mechanism: The fundamental abnormality in FSGS is podocyte injury, dysfunction, and loss. Podocytes are specialized epithelial cells that form the glomerular filtration barrier.
    1. Podocyte Injury: Various insults (genetic mutations, circulating factors, viral infections, drugs, mechanical stress from hyperfiltration) directly damage podocytes.
    2. Podocyte Detachment/Depletion: Damaged podocytes detach from the glomerular basement membrane (GBM) or undergo apoptosis, leading to areas of GBM denudation.
    3. Glomerular Collapse/Scarring: Denuded areas of GBM are exposed to the Bowman's capsule, leading to adhesion formation between the glomerular tuft and Bowman's capsule. Mesangial cells and fibroblasts migrate into these areas, laying down extracellular matrix, resulting in focal and segmental sclerosis.
    4. Proteinuria: Compromised podocyte barrier function leads to increased permeability to proteins, resulting in proteinuria, the hallmark of nephrotic syndrome.
    5. Progression: Loss of functional nephrons due to scarring leads to compensatory hyperfiltration in remaining nephrons, which can, in turn, cause further podocyte injury and accelerate progression to ESRD. * Circulating Permeability Factor (Primary FSGS): While not fully identified, evidence suggests a circulating factor (e.g., suPAR - soluble urokinase plasminogen activator receptor, or cardiotrophin-like cytokine factor 1 - CLCF1) may contribute to podocyte injury and proteinuria in primary FSGS. This is supported by recurrence post-transplant and response to plasmapheresis.
  • Risk Factors:
    • Genetic Predisposition: Family history of FSGS, mutations in podocyte-related genes (e.g., NPHS2 - podocin, TRPC6, WT1, INF2).
    • African Ancestry: Higher incidence, greater severity, and worse prognosis, potentially due to genetic variants (e.g., APOL1 G1/G2 risk alleles).
    • Obesity: A significant and growing cause of secondary FSGS due to hyperfiltration.
    • High Blood Pressure: Contributes to glomerular hyperfiltration and injury.
    • Reduced Nephron Mass: Congenital (e.g., renal agenesis), acquired (e.g., unilateral nephrectomy, reflux nephropathy), leading to compensatory hyperfiltration.
    • Certain Medications: Lithium, pamidronate, heroin, anabolic steroids, interferons.
    • Viral Infections: HIV, parvovirus B19, CMV, EBV.
    • Sickle Cell Anemia: Renal involvement often includes FSGS.
    • Autoimmune Diseases: Rare associations with SLE, vasculitis.
  • Protective Factors:
    • For primary FSGS, specific "protective factors" are not well-defined. However, early diagnosis and appropriate immunosuppressive therapy can significantly improve outcomes and prevent progression.
    • For secondary FSGS, preventing or managing the underlying cause acts as a protective measure (e.g., maintaining healthy weight, controlling blood pressure, avoiding nephrotoxic drugs, antiretroviral therapy for HIV).
    • General kidney protective measures: maintaining good blood pressure control, glycemic control in diabetics, limiting high-protein diets in advanced CKD, avoiding nephrotoxic agents.

Clinical Presentation

Signs and Symptoms

  • Cardinal Features:
    • Proteinuria: The hallmark. Often in the nephrotic range (≥3.5 g/24 hours or urine protein:creatinine ratio ≥3.5 mg/mg). Can be non-nephrotic.
    • Edema: Peripheral edema (pitting edema in ankles, legs), periorbital edema, scrotal edema, ascites, pleural effusions, due to hypoalbuminemia and fluid retention.
    • Hypoalbuminemia: Serum albumin <3.0 g/dL, often <2.5 g/dL.
    • Hyperlipidemia: Elevated total cholesterol, LDL, triglycerides, due to increased hepatic synthesis of lipoproteins in response to low oncotic pressure and decreased catabolism.
  • Early Signs:
    • Insidious onset of edema (puffy eyelids in the morning, swelling of ankles by evening).
    • Foamy urine (due to heavy proteinuria).
    • Generalized fatigue or malaise.
  • Advanced Signs:
    • Significant anasarca (generalized massive edema).
    • Hypertension (in approximately 50% of patients).
    • Progressive decline in glomerular filtration rate (GFR), leading to symptoms of uremia (nausea, vomiting, anorexia, altered mental status) if ESRD develops.
    • Symptoms of complications such as venous thromboembolism (e.g., shortness of breath, chest pain, calf pain).
  • Atypical Presentations:
    • Isolated non-nephrotic proteinuria with microscopic hematuria.
    • Rapidly progressive renal failure (especially with the collapsing variant).
    • Minimal or no edema, despite significant proteinuria (more common in secondary FSGS or early stages).

Physical Examination

  • Inspection:
    • Edema: Pitting edema (especially dependent areas like ankles, sacrum, pretibial), periorbital edema, generalized anasarca.
    • Skin: Pallor (due to anemia of CKD), xanthomas/xanthelasmas (due to severe hyperlipidemia, rare).
    • Abdomen: Ascites (distended abdomen, fluid wave, shifting dullness).
    • Respiratory: Pleural effusions (diminished breath sounds, dullness to percussion).
  • Palpation:
    • Edema: Pitting quality of edema.
    • Cardiac: Signs of cardiomegaly (displaced apex beat), fluid overload (gallop rhythm).
  • Special Tests:
    • Blood Pressure Measurement: To detect hypertension.
    • JVP Assessment: To assess fluid volume status (elevated in fluid overload).
    • Fundoscopy: To assess for hypertensive retinopathy or signs of other systemic diseases if suspected.
    • Deep Tendon Reflexes: Can be diminished in severe hypoalbuminemia (less common) or if electrolyte derangements exist.

Diagnostic Approach

History Taking

  • Key Questions:
    • Symptoms of Nephrotic Syndrome: Onset, progression, severity of edema, foamy urine, fatigue.
    • Drug History: Current and past medications (NSAIDs, lithium, heroin, pamidronate, anabolic steroids, interferons).
    • Family History: Any family members with kidney disease, especially FSGS or early ESRD.
    • Medical History: Diabetes, hypertension, autoimmune diseases (e.g., SLE), viral infections (HIV, hepatitis), obesity, prior nephrectomy, sickle cell disease, congenital anomalies of the kidney and urinary tract (CAKUT).
    • Social History: Illicit drug use (heroin), travel history (for infectious causes).
    • Review of Systems: Symptoms suggestive of systemic illness (e.g., rash, joint pain for autoimmune disease, fever, night sweats for infection).
  • Red Flags:
    • Rapidly progressive edema and weight gain.
    • Symptoms of acute kidney injury (oliguria, anuria, uremic symptoms).
    • Signs of deep vein thrombosis or pulmonary embolism (leg pain/swelling, sudden shortness of breath, chest pain).
    • Severe hypertension.
    • Evidence of systemic illness requiring urgent investigation.

Laboratory Tests

  • First-Line:
    • Urinalysis: Dipstick for proteinuria (often 3+ or 4+), microscopic hematuria (variable, present in 20-30%).
    • 24-hour Urine Protein Collection or Urine Protein:Creatinine Ratio (UPCR): To quantify proteinuria. Nephrotic range proteinuria is ≥3.5 g/24h or UPCR ≥3.5 mg/mg (or 3500 mg/g).
    • Serum Creatinine and eGFR: To assess kidney function.
    • Serum Albumin: To assess severity of hypoalbuminemia.
    • Lipid Panel: Total cholesterol, LDL, HDL, triglycerides (typically elevated).
    • Complete Blood Count (CBC): To check for anemia (common in CKD).
    • Electrolytes: Na, K, Cl, Bicarbonate (to assess for imbalances, e.g., hyperkalemia in advanced CKD).
  • Confirmatory:
    • Kidney Biopsy (Gold Standard): Essential for diagnosis, classification of FSGS variant, and ruling out other glomerular diseases.
      • Light Microscopy: Segmental areas of glomerular sclerosis, often with hyalinosis. Immunofluorescence typically negative or non-specific (IgM, C3 deposition in sclerotic areas).
      • Electron Microscopy: Podocyte foot process effacement (diffuse in primary FSGS, focal/patchy in secondary).
  • Monitoring:
    • Serum Creatinine/eGFR: Regularly to monitor kidney function and disease progression (e.g., every 1-3 months depending on stability).
    • Urinary Protein (UPCR or 24h collection): To monitor response to therapy and disease activity (e.g., monthly initially, then every 3-6 months).
    • Serum Albumin: To monitor nutritional status and response to therapy.
    • Lipid Panel: To monitor hyperlipidemia and efficacy of lipid-lowering therapy.
    • Blood Pressure: Regularly.
    • Drug-specific monitoring: For immunosuppressants (e.g., cyclosporine/tacrolimus levels, CBC and LFTs for MMF, blood glucose and bone density for steroids).

Imaging

  • Recommended:
    • Renal Ultrasound: To assess kidney size, cortical echogenicity (increased echogenicity indicates chronicity), and rule out obstructive uropathy. Kidneys are typically normal or slightly enlarged in early FSGS, but become small and echogenic with advanced CKD.
  • Advanced:
    • Doppler Ultrasound of Renal Veins: If renal vein thrombosis is suspected (e.g., sudden worsening of proteinuria, flank pain, hematuria).
    • Computed Tomography (CT) or Magnetic Resonance Imaging (MRI): Rarely indicated for FSGS diagnosis, but may be used to evaluate for causes of secondary FSGS (e.g., retroperitoneal fibrosis, tumors) or complications.

Management

Management depends heavily on the classification (primary vs. secondary) and the severity of disease. The primary goals are to induce remission of proteinuria, preserve kidney function, and manage complications.

Acute Management

  • Immediate:
    • Severe Edema/Anasarca: Loop diuretics (e.g., furosemide 40-160 mg IV/oral, titrated to effect) to reduce fluid overload. In severe hypoalbuminemia (<2.0-2.5 g/dL), albumin infusion (e.g., 25g albumin IV over 30-60 min) followed by furosemide can optimize diuretic response, but benefits are transient and controversial for routine use.
    • Hypertensive Crisis: IV antihypertensives (e.g., labetalol, nicardipine) if severe hypertension.
  • Stabilization:
    • Acute Kidney Injury (AKI): Address reversible causes (e.g., hypovolemia, nephrotoxic drugs). May require temporary dialysis if severe uremia, intractable fluid overload, or hyperkalemia.
    • Thromboembolism Prophylaxis: Consider prophylactic anticoagulation in high-risk patients (e.g., serum albumin <2.5 g/dL, severe proteinuria, immobility, history of VTE, obesity) with unfractionated heparin or LMWH, if not contraindicated.
  • Emergency:
    • Pulmonary Embolism (PE): Prompt anticoagulation with LMWH or unfractionated heparin, followed by oral anticoagulation. Thrombolysis or embolectomy in massive PE.
    • Severe Sepsis/Infection: Broad-spectrum antibiotics, fluid resuscitation, vasopressors as needed.

Chronic Management

I. Management of Primary FSGS (Idiopathic)

The cornerstone of primary FSGS treatment is immunosuppression, especially for patients with nephrotic syndrome.

  • First-Line Immunosuppression (for Nephrotic Syndrome):
    • Corticosteroids:
      • Standard Regimen: Prednisone 1 mg/kg/day (maximum 60-80 mg/day) orally, for a minimum of 4-6 months, or until complete remission.
      • Response: Taper slowly over several months after remission, typically aiming for a total duration of 6-9 months or longer.
      • Methylprednisolone: High-dose IV methylprednisolone pulse therapy (e.g., 0.5-1 g IV daily for 3 days) may be considered for severe or rapidly progressive cases, followed by oral prednisone.
      • Side Effects: Weight gain, hyperglycemia, hypertension, osteoporosis, cataracts, infections, mood changes.
  • Second-Line Immunosuppression (for Steroid-Resistant or Steroid-Dependent Cases):
    • Calcineurin Inhibitors (CNIs): Used for patients who fail to achieve remission after an adequate trial of steroids (steroid-resistant) or relapse during steroid taper (steroid-dependent), or as steroid-sparing agents.
      • Cyclosporine (CSA): Initial dose 3-5 mg/kg/day orally in two divided doses. Target trough levels: 100-200 ng/mL. Duration typically 12-24 months.
      • Tacrolimus (TAC): Initial dose 0.05-0.1 mg/kg/day orally in two divided doses. Target trough levels: 5-10 ng/mL. Duration typically 12-24 months.
      • Monitoring: Regular monitoring of serum creatinine, CNI trough levels, blood pressure, electrolytes.
      • Side Effects: Nephrotoxicity (dose-dependent), hypertension, hirsutism (CSA), gingival hypertrophy (CSA), neurotoxicity, diabetes (TAC), infections.
    • Mycophenolate Mofetil (MMF):
      • Dose: 1-1.5 g orally twice daily.
      • Role: Less effective as monotherapy for initial steroid-resistant FSGS, but may be useful in CNI-intolerant patients, or as an adjunct, or for maintenance after CNI withdrawal.
      • Side Effects: Gastrointestinal upset (nausea, diarrhea), bone marrow suppression (leukopenia).
    • Rituximab:
      • Dose: 375 mg/m² IV weekly for 4 doses, or 1 g IV given twice, 2 weeks apart.
      • Role: Emerging data suggests it may be effective in some patients with primary FSGS, particularly those who are steroid-dependent or CNI-resistant/intolerant. More studies needed.
      • Side Effects: Infusion reactions, infections (including progressive multifocal leukoencephalopathy - PML, rarely).
    • Cyclophosphamide: Reserved for highly resistant cases, especially those with collapsing variant or rapidly progressive disease, given its toxicity. Dose 1-2 mg/kg/day orally.

II. Management of Secondary FSGS

  • Address the Underlying Cause:
    • Drug-induced: Discontinue the offending drug.
    • Viral-associated: Antiviral therapy (e.g., ART for HIV-associated nephropathy).
    • Adaptive/Hyperfiltration:
      • Weight reduction for obesity-related FSGS.
      • Strict blood pressure control.
      • RAAS blockade.
    • Genetic: No specific immunosuppressive therapy. Management focuses on supportive care, RAAS blockade, and managing complications.

III. Non-pharmacological Management (Supportive Care)

  • Renin-Angiotensin-Aldosterone System (RAAS) Blockade:
    • ACE Inhibitors (ACEi) or Angiotensin Receptor Blockers (ARBs): Essential for all patients with proteinuria, regardless of blood pressure. Reduces proteinuria and slows progression of kidney disease.
    • Dosing: Start with low dose and titrate upwards to maximal tolerated dose or until proteinuria reduction is achieved, while monitoring blood pressure and potassium.
    • Examples: Lisinopril 10-40 mg daily, Losartan 50-100 mg daily.
  • Diuretics:
    • Loop Diuretics (e.g., Furosemide, Torsemide, Bumetanide): For management of edema. Dose titration based on fluid status and urine output.
    • Thiazide Diuretics (e.g., Hydrochlorothiazide, Metolazone): Can be added to loop diuretics in refractory edema.
  • Lipid Management:
    • Statins: HMG-CoA reductase inhibitors (e.g., Atorvastatin 20-80 mg daily, Rosuvastatin 10-40 mg daily) are indicated for hyperlipidemia to reduce cardiovascular risk.
  • Dietary Modifications:
    • Sodium Restriction: <2 grams/day to help manage edema and hypertension.
    • Fluid Restriction: If hyponatremia or severe edema despite diuretics.
    • Protein Intake: Usually not restricted initially. If advanced CKD (eGFR <30 mL/min), moderate protein restriction (0.8 g/kg/day) might be considered.
  • Blood Pressure Control: Target BP typically <130/80 mmHg, often lower for significant proteinuria (<120/70 mmHg). RAAS blockade is the preferred first-line agent.
  • Anticoagulation: Prophylactic anticoagulation may be considered in high-risk patients (serum albumin <2.5 g/dL, especially with other risk factors like immobility, obesity, prior thromboembolism). Oral anticoagulants (warfarin, DOACs) may be used for established thromboembolism.

Treatment Algorithms

  • First-Line (Primary FSGS with Nephrotic Syndrome):
    1. Rule out secondary causes (history, serologies, consider genetic testing for early onset/familial cases).
    2. Corticosteroids: Prednisone 1 mg/kg/day (max 60-80 mg) for 4-6 months or until complete remission. Taper slowly.
    3. Supportive care: RAAS blockade, diuretics, statins, salt restriction, BP control.
  • Second-Line (Steroid-Resistant or Steroid-Dependent Primary FSGS):
    1. Steroid-Resistant (no remission after 4-6 months):
      • Calcineurin Inhibitor (CNI): Cyclosporine or Tacrolimus for 12-24 months.
      • Consider a repeat biopsy: To confirm diagnosis or identify a different pattern, especially if initial biopsy was small or atypical.
    2. Steroid-Dependent (relapse during taper or maintenance):
      • CNI: Cyclosporine or Tacrolimus to allow steroid withdrawal.
      • Mycophenolate Mofetil (MMF): Can be considered, especially if CNI intolerant, but often less effective as monotherapy.
      • Rituximab: Emerging role for some steroid-dependent/resistant cases.
  • Refractory Cases (No remission despite steroids and CNI):
    1. Consider alternative agents: Rituximab, MMF (if not tried), or cyclophosphamide (with caution due to toxicity).
    2. Genetic testing: Essential if not done, as genetic FSGS does not respond to immunosuppression.
    3. Renal transplantation: If ESRD develops. Recurrence in transplant is a significant risk for primary FSGS (up to 30-50%), managed with plasmapheresis and rituximab.

Complications

  • Common:
    • Edema/Fluid Overload: Peripheral, periorbital, pulmonary edema, ascites, pleural effusions.
    • Hyperlipidemia: Elevated cholesterol and triglycerides, increasing cardiovascular risk.
    • Hypertension: Common, contributes to disease progression and cardiovascular events.
    • Increased Risk of Infection: Due to loss of immunoglobulins in urine, impaired cellular immunity, and immunosuppressive therapy.
    • Thromboembolism: Due to urinary loss of anticoagulant proteins (e.g., antithrombin III), increased platelet aggregation, and hyperfibrinogenemia. Most common sites: DVT, PE, renal vein thrombosis.
  • Serious:
    • End-Stage Renal Disease (ESRD): The most serious long-term complication, requiring dialysis or kidney transplantation.
    • Acute Kidney Injury (AKI): Can be superimposed on CKD due to hypovolemia, medications, or rapidly progressive disease.
    • Cardiovascular Disease: Accelerated atherosclerosis due to hyperlipidemia, hypertension, and chronic inflammation. Leading cause of morbidity and mortality.
    • Anemia: Due to CKD (erythropoietin deficiency, iron deficiency).
    • Bone Mineral Disease: Renal osteodystrophy.
  • Long-term:
    • ESRD and need for renal replacement therapy.
    • Complications of immunosuppression: Increased risk of infection, malignancy, diabetes, osteoporosis, cataracts, CNI nephrotoxicity, etc.
    • Recurrence post-transplant: Significant issue for primary FSGS, often presenting as immediate proteinuria.

Prognosis

  • Factors Affecting Outcome:
    • Proteinuria at Diagnosis: Higher levels (especially >8-10 g/day) are associated with worse prognosis.
    • Response to Therapy: Complete or partial remission of proteinuria is the strongest predictor of good long-term renal survival.
    • GFR at Diagnosis: Lower GFR at diagnosis indicates more advanced disease and worse prognosis.
    • Histological Variant: Collapsing variant has the worst prognosis (rapid progression to ESRD), Tip variant has the best prognosis, and NOS/Cellular/Perihilar are intermediate.
    • Race/Ethnicity: African Americans tend to have a worse prognosis, partly due to genetic factors (APOL1 risk alleles).
    • Presence of Interstitial Fibrosis/Tubular Atrophy on Biopsy: Indicates chronic damage and predicts worse outcomes.
    • Hypertension at Presentation: Poor prognostic factor.
    • Age at Onset: Younger age (pediatric) often associated with better response to steroids, but genetic forms can have poor outcomes.
  • Survival:
    • Without treatment, a significant proportion of patients with primary FSGS (50-70%) progress to ESRD within 5-10 years.
    • With treatment, complete or partial remission can be achieved in 50-70% of patients, significantly improving renal survival.
    • 5-year renal survival rates are around 70-80% for those achieving remission, compared to 20-30% for non-responders.
  • Quality of Life: Significantly impacted by symptoms of nephrotic syndrome (edema, fatigue), side effects of immunosuppression, complications (infections, thromboembolism), and the burden of chronic kidney disease or ESRD. Achieving remission improves quality of life.

Prevention

  • Primary Prevention:
    • For primary FSGS, there are no known primary preventive measures as the etiology is idiopathic.
    • For secondary FSGS, primary prevention involves addressing the underlying risk factors:
      • Maintaining a healthy weight to prevent obesity-related FSGS.
      • Strict blood pressure control to prevent hypertensive nephropathy and hyperfiltration injury.
      • Avoiding nephrotoxic drugs (e.g., heroin, unprescribed pamidronate).
      • Early diagnosis and treatment of underlying conditions (e.g., HIV).
      • Genetic counseling for families with known genetic forms of FSGS.
  • Secondary Prevention:
    • Early Diagnosis: Prompt recognition of proteinuria and nephrotic syndrome.
    • Kidney Biopsy: Timely renal biopsy to establish the diagnosis and differentiate primary from secondary FSGS, guiding appropriate treatment.
    • Aggressive Management of Proteinuria: Initiating specific immunosuppressive therapy for primary FSGS and RAAS blockade for all forms of proteinuria to slow disease progression.
    • Regular Monitoring: Close follow-up of kidney function, proteinuria, and blood pressure.
  • Tertiary Prevention:
    • Management of Complications: Prophylaxis against thromboembolism, aggressive treatment of infections, management of hyperlipidemia and hypertension to reduce cardiovascular risk.
    • Slowing Progression to ESRD: Continued RAAS blockade, careful titration of immunosuppression, and adherence to supportive measures.
    • Preparation for Renal Replacement Therapy: Timely referral to transplant centers, dialysis access planning, and patient education once ESRD is imminent.

Special Populations

  • Pediatric:
    • FSGS is a common cause of steroid-resistant nephrotic syndrome in children.
    • Higher rates of genetic FSGS, especially in steroid-resistant cases (e.g., NPHS2 mutations). Genetic testing is highly recommended for steroid-resistant pediatric FSGS.
    • Often respond well to steroids initially, but relapses are common.
    • CNIs (cyclosporine, tacrolimus) are standard second-line agents.
    • Long-term monitoring for growth, bone health, and neurocognitive development is crucial due to chronic illness and steroid use.
  • Geriatric:
    • FSGS incidence increasing in older adults, often presenting with secondary forms (e.g., adaptive, vascular disease-related).
    • More comorbidities (diabetes, hypertension, cardiovascular disease) requiring careful consideration of immunosuppressive side effects.
    • Increased susceptibility to infections and other adverse effects of corticosteroids and CNIs. Dosing may need adjustment based on GFR and overall health.
    • A more conservative approach to immunosuppression may be considered in frail elderly patients, balancing benefits and risks.
  • Pregnancy:
    • FSGS can complicate pregnancy, with risk of increased proteinuria, hypertension, and pre-eclampsia/eclampsia.
    • Proteinuria often increases during pregnancy. Close monitoring of kidney function, blood pressure, and proteinuria.
    • Immunosuppressants:
      • Corticosteroids: Generally considered safe.
      • Calcineurin Inhibitors (CNIs): Cyclosporine and Tacrolimus can be continued, but close monitoring of maternal and fetal levels, blood pressure, and kidney function is necessary.
      • ACEi/ARBs: Contraindicated due to fetal nephrotoxicity. Must be discontinued before conception or immediately upon pregnancy confirmation.
      • MMF: Contraindicated due to teratogenicity.
    • Higher risk of prematurity and fetal growth restriction.
  • Comorbidities:
    • Diabetes: Concurrent diabetes and FSGS worsens prognosis. Strict glycemic and BP control are paramount. Avoid steroids if possible or use low doses, as they can worsen hyperglycemia.
    • Hypertension: Aggressive blood pressure control using RAAS blockade is crucial to mitigate progression.
    • Obesity: Weight loss is critical for obesity-related FSGS to reduce hyperfiltration and improve outcomes. Bariatric surgery may be considered in severe obesity.
    • HIV: HIV-associated nephropathy (HIVAN) is a distinct collapsing variant of FSGS. Aggressive antiretroviral therapy (ART) is the cornerstone of treatment and can stabilize or improve kidney function. Immunosuppression is usually not indicated for HIVAN itself.

Clinical Pearls

  • Diagnostic:
    • Always consider secondary causes: Before labeling as primary FSGS, perform thorough history (drugs, family, infections) and serologic work-up. Genetic testing is increasingly important, especially in children or steroid-resistant cases.
    • Biopsy is key: FSGS is a histological diagnosis. Ensure adequate core samples for light microscopy, immunofluorescence, and electron microscopy. Small biopsy samples can miss focal lesions.
    • Foot process effacement: The extent of foot process effacement on electron microscopy is crucial. Diffuse effacement suggests active primary FSGS; patchy effacement points to secondary forms.
  • Treatment:
    • Response is everything: Achieving complete or partial remission of proteinuria is the most important prognostic indicator. Aim for remission.
    • Steroids first: For primary nephrotic FSGS, corticosteroids remain the first-line treatment. Give adequate duration (4-6 months) before labeling as steroid-resistant.
    • CNI monitoring: If using CNIs, vigilant monitoring of trough levels, blood pressure, and renal function is critical to balance efficacy and minimize nephrotoxicity.
    • RAAS blockade: Don't underestimate the power of ACEi/ARBs in reducing proteinuria and slowing progression, regardless of the cause of FSGS. It should be used in almost all patients with proteinuria.
    • Individualize therapy: Treatment regimens must be tailored based on patient age, comorbidities, histological variant, and response to previous therapies.
  • Pitfalls:
    • Prematurely discontinuing steroids: Leads to relapse and worse outcomes. Tapering should be slow and guided by response.
    • Ignoring secondary causes: Treating a secondary FSGS with heavy immunosuppression can be ineffective and harmful.
    • Not monitoring for complications: Missing VTE, infections, or cardiovascular disease can lead to severe morbidity/mortality.
    • Insufficient RAAS blockade: Under-dosing or not using ACEi/ARBs when indicated.
    • Overlooking APOL1 status: Especially in African American patients, APOL1 risk alleles can predict steroid resistance and higher risk of progression, guiding counseling and potentially therapeutic choices.

Recent Updates

  • Guidelines:
    • KDIGO (Kidney Disease: Improving Global Outcomes) guidelines provide comprehensive recommendations for glomerular diseases, including FSGS. The most recent version is from 2021 (Glomerular Diseases).
    • ERA-EDTA (European Renal Association - European Dialysis and Transplant Association) also offers clinical practice guidelines.
    • Key updates focus on: Better distinction between primary and secondary FSGS, expanded role for genetic testing, individualized immunosuppression strategies, and emphasis on supportive care.
  • Evidence:
    • Genetic Discoveries: Continued identification of new genes associated with FSGS (e.g., INF2, COQ6, PAX2).
    • APOL1 Risk Alleles: Strong evidence confirming the association of APOL1 G1/G2 risk alleles with increased risk of FSGS and faster progression, particularly in individuals of African ancestry. This has implications for prognosis and potentially treatment response.
    • Rituximab: Growing but still limited evidence for its use in primary FSGS, especially for steroid-dependent or CNI-resistant cases. Data are largely from small cohorts and uncontrolled studies.
    • Novel Therapies: Research is ongoing into novel agents targeting podocyte injury or inflammation, such as abatacept (CTLA-4Ig) and medications targeting suPAR or other circulating factors, though these are not standard of care yet.
    • SGLT2 Inhibitors: While not directly treating the underlying immune process in primary FSGS, SGLT2 inhibitors are showing promise in reducing proteinuria and slowing kidney disease progression in various CKD populations, including those with glomerular disease, and are likely to be increasingly used as an adjunct to RAAS blockade.
  • Controversies:
    • Role of Rituximab: Its exact place in the treatment algorithm (second-line, third-line, or specific populations) and optimal dosing regimen are still under investigation. Some trials show benefit, others do not.
    • Treatment of Genetic FSGS: No immunosuppressive therapy is effective for genetic FSGS. The focus is on supportive care and RAAS blockade.
    • Recurrence post-transplant: Management strategies for recurrent FSGS, including plasmapheresis and rituximab, are effective but optimal protocols are still debated.
    • Biomarkers: The search for a reliable circulating biomarker for primary FSGS (e.g., suPAR) that could predict recurrence or response to therapy is ongoing, but none are clinically established for routine use.

Key References

  • Guidelines:
    • KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney International, 2021.
    • ERA-EDTA Clinical Practice Guidelines on Glomerular Diseases.
  • Studies:
    • NEPTUNE (Nephrotic Syndrome Study Network) cohort studies: Provide valuable insights into FSGS phenotypes, genetics, and responses to therapy.
    • Landmark trials on immunosuppressants in nephrotic syndrome (e.g., those establishing the efficacy of steroids and CNIs in primary FSGS).
    • Studies on APOL1 risk variants and their impact on FSGS.
  • Reviews:
    • Comprehensive reviews in major nephrology journals (e.g., Journal of the American Society of Nephrology (JASN), Kidney International, Nature Reviews Nephrology) on the pathophysiology and management of FSGS.

Disclaimer: This information is for educational purposes only and should not be considered medical advice. Clinical decisions must always be made by a qualified healthcare professional based on the individual patient's condition, medical history, and current evidence. This content is not a substitute for professional medical judgment.

Dr. Vivek's AI | For Educational Purposes Only